BRAIN Biotech AG

XETRA BNN.DE

BRAIN Biotech AG Shareholders' Equity for the year ending September 30, 2024: USD 14.05 M

BRAIN Biotech AG Shareholders' Equity is USD 14.05 M for the year ending September 30, 2024, a -38.97% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • BRAIN Biotech AG Shareholders' Equity for the year ending September 30, 2023 was USD 23.02 M, a -20.75% change year over year.
  • BRAIN Biotech AG Shareholders' Equity for the year ending September 30, 2022 was USD 29.05 M, a -35.30% change year over year.
  • BRAIN Biotech AG Shareholders' Equity for the year ending September 30, 2021 was USD 44.89 M, a 84.30% change year over year.
  • BRAIN Biotech AG Shareholders' Equity for the year ending September 30, 2020 was USD 24.36 M, a 82.71% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
SV Wall Street
XETRA: BNN.DE

BRAIN Biotech AG

CEO Mr. Adriaan Moelker
IPO Date Feb. 9, 2016
Location Germany
Headquarters Darmstädter Strasse 34-36
Employees 319
Sector Healthcare
Industries
Description

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

Similar companies

FYB.DE

Formycon AG

USD 55.66

3.14%

COP.DE

CompuGroup Medical SE & Co. KGaA

USD 23.74

0.16%

MDG1.DE

Medigene AG

USD 1.71

-2.14%

StockViz Staff

February 6, 2025

Any question? Send us an email